Recent ARCT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:17:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:04 PM
- Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress • Business Wire • 05/08/2024 08:01:00 PM
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 • Business Wire • 04/25/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:05:52 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress • Business Wire • 03/07/2024 09:01:00 PM
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 02/26/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:35 PM
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 02/22/2024 01:30:00 PM
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 • Business Wire • 02/20/2024 02:00:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • PR Newswire (US) • 02/05/2024 01:30:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • Business Wire • 02/05/2024 01:30:00 PM
- CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster • Business Wire • 12/21/2023 01:00:00 PM
- CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster • PR Newswire (US) • 12/21/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 01:01:03 AM
- Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/04/2023 01:30:00 PM
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults • PR Newswire (US) • 11/28/2023 01:05:00 PM
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults • Business Wire • 11/28/2023 01:00:00 PM
- Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis • Dow Jones News • 11/27/2023 02:13:00 PM
- Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 11/27/2023 01:30:00 PM
- Keep An Eye Out: Pre-Market Movers And Analyst Recommendations • IH Market News • 11/15/2023 01:51:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:10:46 PM
- Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress • Business Wire • 11/14/2023 09:01:00 PM
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 • Business Wire • 10/25/2023 08:01:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 10/23/2023 08:01:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM